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Summary   
Cognitive performance (Intelligence Quotient) in children and young adults with standard risk 
medulloblastoma in the XXXXX randomised controlled treatment trial were compared between those 
allocated to hyperfractionated (HFRT arm) or standard radiation therapy (STRT arm), followed, in both 
treatment arms, by a standard chemotherapy regimen. Treatment with HFRT was associated with a trend 
towards better verbal outcomes in children aged less than 8 years at diagnosis, but no significant 
differences on the other cognitive measures. 
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Abstract  
Purpose/Objective(s): In the XXX-XXXX XXXXX European randomised controlled trial, children 
with standard risk medulloblastoma were allocated to hyperfractionated (HFRT arm, including a 
partially focussed boost) or standard radiation therapy (STRT arm) followed, in both arms, by 
maintenance chemotherapy. Event-free survival was similar in both arms. Previous work showed that 
HFRT arm was associated with worse growth and better questionnaire-based executive function, 
especially in children aged <8 years at diagnosis. Therefore, the aim of this study was to compare 
performance-based cognitive outcomes between treatment arms. 
Methods and Materials: Neuropsychological data were collected prospectively in 137 patients. Using 
the Wechsler Intelligence Scales, Kaufman Assessment Battery for Children, and Raven’s Progressive 
Matrices, we estimated: Full scale Intelligence Quotient (IQ) and, when available, Verbal IQ, 
Performance IQ, Working Memory Index (WMI), and Processing Speed Index (PSI).  
Results: Among the 137 participants [HFRT arm n=71, STRT arm n=66, 63.5% males], mean (SD) 
age at diagnosis and assessment respectively was 9.3 years (3.2) (40.8% aged <8 years at diagnosis), 
and 14.6 years (4.3). Mean (SD) FSIQ was 88 (19) and mean intergroup difference was [95% CIs] 
3.88 [-2.66 to 10.42, p=.24]. No significant difference was found in children aged >8 years at 
diagnosis. In children aged <8 at diagnosis, a marginally significant trend towards higher VIQ was 
found in those treated in the HFRT arm; a similar trend was found for PSI but not for PIQ, WMI or 
FSIQ (mean inter-group differences [95% CIs]): VIQ (12.02 [2.37 to 21.67]) p=0.02; PIQ (3.77 [-5.19 
to 12.74]) p>.10; WMI (5.20 [-2.07 to 12.47]) p>.10; PSI (10.90 [-1.54 to 23.36]) p=.08; FSIQ (5.28 [-
4.23 to 14.79]) p>.10. 
Conclusions: HFRT arm was associated with marginally higher VIQ in children aged <8 years at 
diagnosis, consistent with the previous report using questionnaire-based data. However, overall 
cognitive ability was not significantly different.  
 
Key words: child, medulloblastoma, XXXX, chemotherapy, radiotherapy, outcome, cognitive 
function, intellectual ability, verbal ability, perceptive reasoning, processing speed, working memory, 
quality of survival. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Cognitive performance in the XXXXX study 
 
2 
 
Introduction  
Extensive research has consistently recognized longitudinal impairments associated with medulloblastoma 
(MB), the most frequent malignant brain tumour of the central nervous system (CNS) during childhood1–3. 
Standard treatment includes surgical resection, postoperative radiotherapy (RT) and adjuvant 
chemotherapy. Medulloblastoma survivors experience significant health-related problems, namely 
endocrine and growth morbidity and reduced fertility4,5, second tumours6, hearing loss7,  and long-term 
neurological deficits8–10. Among the major complications arising from the tumour and its treatment, 
predominantly radiotherapy and especially when given with chemotherapy, are the high rate of 
neurocognitive deficits, possibly attributable to the deleterious effects of radiation on white matter 
development11,12. MB survivors typically achieve scores below the mean of age-matched peers in measures 
of Intelligence Quotient (IQ), Verbal and Performance IQ, processing speed, working memory and 
sustained attention13–16. Importantly, deficits in these core cognitive domains tend to worsen over time16–18. 
To improve tumour control and quality of survival (QoS), hyperfractionated radiation therapy (HFRT) 
capitalizes on the fact that proliferating tumour cells are more sensitive than normal tissue to a given 
dose of radiotherapy if it is administered in a larger number of fractions of smaller size. This enhances 
the antitumour effects of radiotherapy while sparing normal tissues19-22. Compared with standard 
fractionated treatment (STRT), HFRT can be utilised either to maintain a given anti-tumour effect 
while decreasing unwanted effects on the CNS, or to increase the anti-tumour effect without 
increasing unwanted effects on the CNS. Previous uncontrolled studies of Carrie et al.22 and Gupta et 
al.23 reported higher post-treatment full-scale IQ in patients receiving twice-daily HFRT, compared to 
historical controls receiving once-daily STRT. However, using historical controls instead of a 
controlled experimental randomized design, limits the interpretation of these data.  
Further, we could hypothesise that the lack of a significant IQ decline could be related to improved 
quality of posterior fossa irradiation, even in STRT, with less radiation to the temporal and occipital 
lobes.  
The XXX-XXXX XXXXX phase 3 European randomized controlled treatment trial (RCT) for MB was 
designed to investigate the hypothesised biological advantage of HFRT over STRT. Five-year event-free 
survival was similar between the two arms24. A subsequent cross-sectional study assessed quality of 
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survival through questionnaires of executive function, health status, behaviour, health-related quality of life 
(HRQoL) and growth. This study25 indicated significantly better executive functioning for children and 
young adults treated with HFRT compared with STRT, in accordance with Carrie et al.22 and Gupta el al.23. 
No other significant advantage of HFRT was observed for health status, behaviour or HRQoL, and patients 
receiving HFRT had significantly greater deficit in height gain from diagnosis. The differences between 
treatment arms regarding executive functioning and growth impairment were significantly greater in 
patients aged less than 8 years at diagnosis25. The present study aimed to complement these findings by 
examining effects of HFRT and STRT on cognitive outcomes in XXXXX survivors as assessed directly 
using age-appropriate measures of intellectual ability.  
Methods  
Patients 
A population of 338 participants (aged 4-21 years) from 10 countries was randomly assigned to either 
HFRT or STRT for M0 MB between 2001 and 2006.  
STRT comprised 23.4Gy to the craniospinal axis and 54Gy to the posterior fossa given over 42 days in 
30 daily fractions of 1.8Gy for 5 days per week. HFRT was given in 68 fractions: 1.0Gy twice per day 
with an 8-hour interval between fractions, given over 48 days. In the HFRT arm, the total craniospinal 
dose was 36 Gy, and the whole posterior fossa dose was 60 Gy, with a further focused boost of 8 Gy 
to the tumour bed. In both arms, a maximum of 8 doses of vincristine 1.5 mg/m2 (maximum 2mg) was 
given once per week during radiotherapy, followed by adjuvant chemotherapy. Eight cycles of 
cisplatin 70 mg/m2 intravenously, lomustine 75 mg/m2 on day 1, and vincristine 1.5 mg/m2 
intravenously on days 1, 8, and 15, began 6 weeks after the end of RT, with a 6-week interval between 
each cycle24. 
The neuropsychological assessment was not part of the original XXXXX protocol, which comprised 
questionnaire assessments alone. Four of the original 10 participating countries had collected 
prospective or cross-sectional data regarding cognitive outcomes between 2004 and 2013. The 216 
event-free patients from France, Germany, Italy and Sweden who remained in remission during the 9-
month period of the cross-sectional follow-up study conducted by XXXXXXX and colleagues25 were 
eligible for the present analyses and of these, 137 (63.4%) had data regarding cognitive outcomes 
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(71/107 [66.4%] HFRT; 66/109 [60.6%] STRT). A sub-group of 35 participants (25.5%, of 137) had 
had at least two assessments of the same cognitive outcomes (mean delay between evaluations 2.9 
years). For this sub-group, the results of the last assessment were considered for the cross-sectional 
analyses. 
Procedure 
The present study conformed to ethical requirements of all participating countries. Written consent 
was obtained by the treating clinician to conduct cognitive assessments.  
Measures 
Cognitive measures differed according to participants’ age and country. Patients were generally 
evaluated with age-appropriate Wechsler Intelligence Scales26-29. In Germany, age-appropriate 
Raven’s Coloured and Standard Progressive Matrices30, 31, the vocabulary subtests of the Wechsler 
Scales or Kaufmann Assessment Battery for Children32 (K-ABC I/II, Riddles subtest) and the Number 
Recall test of the K-ABC I/II were used to assess children’s performance, verbal and working memory 
abilities, respectively. Five measures of cognitive ability were derived from these assessments: Full 
Scale (FSIQ), Verbal IQ (VIQ) and Performance Intelligence Quotient (PIQ), as well as Working 
Memory (WMI) and Processing Speed Index (PSI, for France, Italy and Sweden only). 
In addition, an adapted version of the Medical Examination form33 addressed to the clinicians and 
information from the Medical Educational Employment and Social (MEES) questionnaire addressed 
to parents and adult participants33 provided information on participant’s baseline demographics and 
secondary outcomes. 
Statistical Analysis 
The effects of treatment allocation on the cognitive measures were evaluated through regression 
models: firstly, for the whole group and, secondly, by age category at diagnosis (<8 or ≥8 years), 
similarly to XXXXXXX and colleagues25. At each step, sex, interval between diagnosis and 
assessment, presence of post-operative complications (or, alternatively, presence of cerebellar mutism) 
was introduced in the regression models, together with treatment allocation.  
Statistical significance testing was 2-tailed with a .003 significance level to adjust for multiple testing 
(Bonferroni correction). However, results with p<.05 and >.003 were categorised as of marginal 
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significance. For the longitudinal analyses, mean differences between first and second assessments 
were compared to zero using paired Student’s t-tests.  
RESULTS 
Group comparisons between participants and non-participants 
Participants with cognitive outcomes and non-participants were similar regarding sex, treatment 
allocation and interval between diagnosis and cognitive assessment. However, non-participants tended 
to be older at diagnosis (mean=11.89 vs. 9.31, p<.01) suggesting that older participants had a lower 
probability of receiving a cognitive assessment. 
Demographic and baseline characteristics for participants 
Participants who received HFRT and STRT were similar regarding sex, age at diagnosis, age at 
assessment, and interval between diagnosis and assessment (Table 1). Regarding pre- and post-
operative characteristics, the two groups were also similar except that a slightly higher rate of post-
operative complications and extra ocular movement deficits was observed in participants receiving 
HFRT compared to those receiving STRT.  
Cognitive outcomes at post-treatment evaluation for the whole group of participants 
The distribution of the five cognitive outcomes indicated considerable variability, with scores ranging 
from 40 to 145. Using a cut-off point of -2 standard deviations, 12.4%, of the FSIQ, 8% of VIQ, 
12.5% of PIQ, 7% of WMI and 33.7% of PSI scores were in the lower extreme range. 
Cognitive outcomes were similar according to sex, country, age at diagnosis, age at assessment, and 
interval between diagnosis and assessment. Mean scores tended to be lower (p<.05 in all cases) in the 
presence of post-operative ataxia: FSIQ (85.01 vs. 94.52), VIQ (89.76 vs. 99.4), WMI (89.34 vs. 
95.29) and PSI (73.82 vs. 85.54). Post-operative cerebellar mutism was associated with lower mean 
PIQ (79.33 vs. 89.09) and PSI (65.83 vs. 81), and extra ocular movements deficits were associated 
with lower mean VIQ (90.37 vs. 98.27, p<.05 in all cases). The presence of any peri-operative 
complications, including cerebellar mutism, was also associated with lower mean scores of PSI (68.75 
vs. 81.14, p=.04). No other differences were observed for the remaining post-operative characteristics. 
Due to these associations, the effects of peri-operative complications (or, alternatively, cerebellar 
mutism) were controlled for in the regression analyses described subsequently. 
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Effects of treatment on cognitive outcomes 
Country by treatment interactions were not significant. In univariate analyses, all cognitive outcomes 
were similar between HFRT and STRT arms (Table 2). However, PSI tended to be higher in the 
HFRT arm (difference (95% CI) 7.9 (-.14 to 15.9), p=.05). In younger participants (<8 years at 
diagnosis) VIQ tended to be higher in the HFRT arm (difference (95% CI) 12.02 (2.4 to 21.7), p=.02). 
For the remaining measures, no other differences were observed between arms when age at diagnosis 
was considered.  
The results of the regression analyses paralleled the univariate analyses described above. In the full 
sample, allocation to HFRT showed a marginally significant trend to higher PSI scores (F=4.74, 
p=.03) and in participants whose age at diagnosis was < 8 years it showed a marginally significant 
association with higher VIQ scores (F=7.1, p=.01). No other significant effect or strong trend 
associated with treatment allocation was found on the remaining cognitive outcomes, either for the 
total sample or for the sub-group of participants whose age at diagnosis was > 8 years. These same 
analyses were redone after exclusion of participants with peri-operative complications and cerebellar 
mutism and results remained unchanged. 
Longitudinal analyses 
Thirty-five participants (25.5% of 137) underwent two cognitive assessments. These participants were 
characterized by longer intervals between diagnosis and the last assessment (p=.01) and higher rates of 
cerebellar mutism (p=.03). None of the remaining baseline characteristics was different between 
participants with cognitive assessment performed at two time points and those who had data at one 
time point. The last assessment was performed at a mean interval from the first evaluation of 2.9 years, 
with the mean interval being similar in both arms. 
Cognitive measures did not differ significantly between Time 1 and Time 2 (Table 3). However, there 
was a tendency for PIQ to increase from the first to the second assessment (difference (95% CI) 5.9 
(1.1 to 10.7, p=.019).  
Moreover, the difference between cognitive outcomes on the two occasions of testing (Time 2 minus 
Time 1) did not differ between HFRT and STRT arms (Table 4). 
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DISCUSSION 
The results suggest that treatment allocation contributed to explain specifically the VIQ scores of 
participants aged less than 8 years at diagnosis. For this subgroup, those allocated to the HFRT arm 
had higher VIQ scores than participants in the STRT arm. Those allocated to HFRT also had a strong 
trend, falling short of statistical significance, to higher PSI scores in the reduced number of 
participants completing this test, both in the sample as a whole and in those aged less than 8 years at 
diagnosis. These effect sizes were large for VIQ and medium for PSI. Other differences between 
treatment arms for the remaining cognitive measures were small and non-significant. Longitudinal 
results, although unpowered, indicated no significant effects of treatment allocation on the cognitive 
outcomes, neither at Time 1 and Time 2, nor from the first to the second assessment.  
In the present study, treatment was randomly allocated and follow-up rates for the cognitive 
assessment were reasonable (63%), which allowed the composition of two heterogeneous groups 
regarding IQ outcomes. However, some limitations should be taken into account. The measures used 
to assess cognitive performance differed according to country and, thus, might reflect distinct 
underlying constructs of cognitive ability. This limitation justifies caution in the interpretation of the 
results and generalization of these findings. Importantly, these results highlight the urgent need for an 
international consensus in the measures used to assess cognitive ability34. Moreover, participants were 
slightly younger at diagnosis than non-participants. However, this difference is not likely to have 
biased our results, since the only significant differences were observed for the subgroup of participants 
with younger age at diagnosis. Furthermore, the analysis per age category had not been planned in the 
initial protocol but was carried out in order to bring complementary information to confirm or refute 
the observation by XXXXXXX and colleagues25 of benefits of HFRT to executive function. Finally, 
results of the regression analyses remained unchanged even when controlling for the marginally 
significant excess of peri-operative complications, namely cerebellar mutism in the HFRT arm. 
The encouraging survival rates of patients treated for MB24 has led researchers to focus on the long-
term consequences of these tumours and their treatment on neurocognitive performance, most often 
focused on overall intellectual ability. Previous research has reported that MB survivors are at 
increased risk for cognitive impairment, with progressive IQ declines typically stabilizing within 1 to 
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2 standard deviations (SD) below the mean of typically age-matched developing peers 5 years after 
treatment13,17,35,36. The results of the present study align well with these prior reports. Collectively, the 
mean scores of all the survivors’ IQ measures allocated either to STRT or HFRT arms fell 1 SD below 
the mean and approximately 10% of the participants evidenced performances 2 SD below the mean 
regardless of treatment. MB survivorship carries lingering effects on the patient’s intellectual 
functioning with significant implication for other domains of QoS, namely academic achievement36, 37. 
An evidence-based conceptual model in which IQ deficits of MB survivors arise secondary to 
underlying impairments in core cognitive skills such as attention, processing speed and working 
memory36, 37 has been proposed.. The deficits observed in PSI for the full sample support this 
contention and suggest that these core cognitive skills might represent developmental precursors to 
overall delays in general cognitive ability. However, the considerable variability of FSIQ (range 40 to 
140, 25% of survivors with IQ ≥ 100) implies that some patients do not follow the expected pathway 
of neurocognitive impairment in accordance with Palmer’s conclusion37. 
XXXXX is the first RCT comparing IQ outcomes between patients who received HFRT versus STRT 
and this study aimed to explore further the effect of treatment on cognitive function recently reported 
by XXXXXXX et al. in XXXXX participants25. Our findings provide support for their observation 
that the effect of radiotherapy on executive function is moderated according to treatment because 
cognitive skills pertaining to information processing speed, working memory and attention represent 
the core developmental precursors of later intellectual and academic function37. 
Taken together with those of XXXXXXX et al, our findings suggest that HFRT arm might result in 
more preserved cognitive function in children aged less than 8 years at diagnosis as suggested by 
previous reports of the greater vulnerability of these children to the adverse effects of treatment on 
neurocognitive outcomes17, 36. These results also parallel those reported by Carrie et al.22 and Gupta et 
al.23 that children treated with HFRT displayed more preserved cognitive functions when compared 
with historical controls. IQ deficits in MB survivors are probably due to a diminished ability to acquire 
new information, rather than the loss of previously acquired knowledge15. Applied to our results, the 
diminished impact of HFRT on young children’s ability to acquire new information represents a 
plausible explanation for their superior VIQ scores, when compared with STRT. Moreover, we also 
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have to take into account that the difference between the two arms was not only the fractionation, but 
also the partially more focused boost in the HFRT arm, which could possibly have led to an increased 
protection of the temporal and occipital lobes. The more focused posterior fossa and primary site boost 
will most likely become a standard procedure38. 
Moreover, our results extend the findings reported by XXXXXXX and colleagues25, who presented 
evidence that survivors allocated to HFRT arm evidenced better scores on the Behavior Rating 
Inventory of Executive Function (BRIEF) global executive composite score than the group that had 
received STRT. Interestingly, Vriezen and Pigott39 reported a significant correlation between VIQ and 
the Metacognition index of the BRIEF questionnaire, i.e., the cognitive sub-scales of this 
questionnaire, in a group of children with traumatic brain injury. However, as argued by XXXXXXX 
and colleagues25, although HFRT survivors obtained higher executive functioning scores than STRT 
survivors, self- or parental reports of behavioural adjustment, HRQoL or health status were 
comparable between treatment groups. As concluded by XXXXXXXXXX and colleagues40, although 
the use of questionnaires might complement information about executive functioning, they might rely 
on a more global frame of everyday functioning and provide less information regarding core cognitive 
processes. Further, in the previous study25, HFRT survivors presented a greater decrement in height 
and reported more use of hearing aids. This difference in the use of hearing aids does not allow us to 
rule out the hypothesis that the better VIQ scores of young children allocated to HFRT could be 
attributed to more appropriate referrals to health services in case of hearing loss.  
The longitudinal analyses indicated that IQ outcomes were not significantly different between the first 
and the second assessments, neither for the full sample nor for each treatment group. On one hand, 
these results follow the findings of Gupta et al.23 who indicated the absence of any decreasing trend on 
measures of FSIQ, VIQ and PIQ for patients allocated to HFRT, when compared with historical 
controls. On the other hand, the results of the analyses performed with the full sample contrasts with 
an established body of literature documenting an IQ decline in MB survivors22, 37, suggesting a 
possible overall improvement of MB treatments, regardless of radiotherapy fractionation, as suggested 
earlier regarding the protection of the temporal and occipital lobes. Nevertheless, our results should be 
interpreted with caution. The small number of patients with two available assessments collected 
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prospectively (mostly in two countries) coupled with the short time between assessment and diagnosis 
limited the ability of the study to detect clinically important differences between treatment arms, 
especially when considering subgroups according to the age at diagnosis. 
In conclusion, this study provides some support to previous observations in the same RCT regarding 
possible benefits of HFRT, when compared to STRT in the XXXXX study, on young children’s verbal 
ability. Although it does not demonstrate a clear advantage of HFRT in the regimen employed, that 
regimen, as comparison with STRT, was designed to be more effective on tumour cells and iso-
effective in its effects on the CNS. The hypothesis that a lower dose regimen of HFRT, designed to be 
iso-effective on tumour cells with decreased adverse effects on the CNS, would bring clinically 
important benefits deserves further exploration with children aged less than 8 years at diagnosis being 
the group most likely to benefit. Further, this study reports detailed findings in patients treated with 
STRT, against which newer treatment approaches could be compared, such as lower CSI doses and a 
tumour bed rather than whole posterior fossa boost.  
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Table 1 
Descriptive statistics of the study’s participants according to treatment allocation    
 HFRT  STRT 
 N M SD Range  N M SD Range 
Demographic characteristics          
Age at diagnosis (years) 71 9.1 3.23 4-17.6  66 9.5 3.14 4.3-17.3 
Age at diagnosis < 8 years, n (%) 31 (43.7)    25 (37.9)   
Age at assessment    1 71 14.3 4.48 6.2-24.9  66 14.9 4.11 6.1-24.7 
Interval from diagnosis (years) 71 5.2 2.81 .08-9.9  66 5.4 2.53 .58-10.5 
Males, n (%) 46 (64.8)    41 (62.1)   
Premorbid developmental 
impairment, n (%)   2 2 (2.8)    4 (6.1)   
Postoperative status          
Post-operative  
complications,  n (%) 3   
10 (14.1)    3 (4.6)   
Impaired consciousness, n (%) 4 0 (0)    2 (3.1)   
Impaired nerve III, n (%) 5 35 (53)    23 (37.7)   
Ataxia, n (%)   6 34 (58.6)    36 (64.3)   
Cerebellar mutism, n (%) 7 6 (8.5)    3 (4.6)   
† Student’s t-test; †† Khi-2 de Mantel-Haenszel. 
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Table 2 
Mean differences of cognitive outcomes according to treatment allocation and age at diagnosis.    
 HFRT  STRT  
 N M SD Range  N M SD Range p † 
             
FSIQ 71 90.3 19.7 40-137  66 86.4 18.9 40- 122 .24 
FSIQ (age > 8) 40 90.7 21.8 40-137  41 87.6 19.3 40-118 .49 
FSIQ (age < 8) 31 89.7 16.8 65.5-128.5  25 84.5 18.6 40-122 .27 
VIQ 58 96.3 17.1 55-128  55 92.4 20.6 43-145 .28 
VIQ (age > 8) 31 95.8 17.4 55-128  34 97.1 22.1 47-145 .79 
VIQ (age < 8) 27 96.8 17.1 60-126  21 84.8 15.7 43-112 .02 
PIQ 70 89.7 21 40-140  66 87.1 17.1 40-122 .43 
PIQ (age > 8) 39 90.4 24.6 40-140  41 88.3 16.8 40-118 .66 
PIQ (age < 8) 31 88.9 15.8 65-128.5  25 85.1 17.7 41-122 .40 
WMI 68 92.3 13.8 55-124  61 89.1 15.3 55-120 .21 
WMI (age > 8) 38 90 14.8 55-124  39 88.6 16.1 56-120 .69 
WMI (age < 8) 30 95.2 11.9 65-118  22 90 14.2 55-110 .16 
PSI 29 83.3 14.7 50-112  28 75.4 15.5 50-100 .05 
PSI (age > 8) 18 81.1 15.6 50-112  17 75.1 16.3 50-100 .27 
PSI (age < 8) 11 86.8 13.1 62-103  11 75.9 14.8 50-96 .08 
† Student’s t-test; FSIQ: Full Scale Intelligence Quotient; VIQ: Verbal Intelligence Quotient; PIQ: Performance 
 Intelligence Quotient; WMI: Working Memory Index; PSI: Processing Speed Index. 
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Table 3 
Time interval and difference in cognitive outcome scores between first and second assessments 
 Time 2 - Time 1   
 N Mean SD Range  p† 
Interval between assessment (yrs) 32 2.9 1.8 .92-7   
FSIQ 33 .18 10.3 -23-18  .92 
VIQ 34 -1.7 13.7 -31-25  .47 
PIQ 35 5.9 14.4 -25-26  .02 
PSI 26 -3.1 12.8 -28-20  .22 
Nb. Due to missing data, WMI was not considered in these analyses; † Paired student’s t-test; FSIQ: Full Scale  
Intelligence Quotient; VIQ: Verbal Intelligence Quotient; PIQ: Performance Intelligence Quotient; PSI:  
Processing Speed Index. 
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Table 4 
Mean comparisons of Time 1 and Time 2 cognitive outcomes by treatment allocation    
 Time 1  Time 2  Time 2 - Time 1  
 HFRT  STRT  HFRT  STRT  HFRT  STRT  
 N M SD  N M SD  N M SD  N M SD  N M SD  N M SD p † 
FSIQ 16 95.3 14.9  18 86.4 13.9  16 96.8 19.1  17 86.5 15.6  16 1.6 12.3  17 -1.1 8.2 .47 
VIQ 16 103.6 15.1  18 90.8 15  16 101.2 17.8  18 89.7 20  16 -2.4 15.1  18 -1.1 12.8 .78 
PIQ 16 88.4 16.9  19 85.5 14.9  16 98.7 19  19 87.8 11.9  16 10.3 14.7  19 2.3 13.4 .10 
PSI 13 89.5 17.7  13 84.3 16.4  14 86.8 13.9  14 77 15.9  13 -1.1 11.9  13 -5.2 13.8 .42 
†Paired student’s t-test. 
 
